Halozyme Therapeutics, Inc. (NASDAQ:HALO) to Post Q3 2022 Earnings of $0.51 Per Share, Zacks Research Forecasts

Halozyme Therapeutics, Inc. (NASDAQ:HALOGet Rating) – Analysts at Zacks Research dropped their Q3 2022 EPS estimates for shares of Halozyme Therapeutics in a report released on Monday, September 19th. Zacks Research analyst I. Bandyopadhyay now expects that the biopharmaceutical company will post earnings of $0.51 per share for the quarter, down from their prior estimate of $0.56. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $1.92 per share.

A number of other research firms also recently commented on HALO. Morgan Stanley started coverage on shares of Halozyme Therapeutics in a report on Friday, September 9th. They issued an “overweight” rating and a $50.00 target price on the stock. The Goldman Sachs Group boosted their target price on shares of Halozyme Therapeutics from $48.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, May 26th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $52.00.

Halozyme Therapeutics Stock Down 1.2 %

NASDAQ HALO opened at $38.74 on Thursday. The company has a debt-to-equity ratio of 3.91, a current ratio of 2.72 and a quick ratio of 2.23. The company’s 50 day simple moving average is $43.96 and its 200 day simple moving average is $43.05. Halozyme Therapeutics has a 12 month low of $31.36 and a 12 month high of $52.98. The company has a market capitalization of $5.34 billion, a P/E ratio of 15.31, a PEG ratio of 0.68 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALOGet Rating) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.06. Halozyme Therapeutics had a net margin of 75.11% and a return on equity of 101.73%. The company had revenue of $152.37 million for the quarter, compared to the consensus estimate of $156.00 million. During the same period in the previous year, the firm earned $0.63 EPS. Halozyme Therapeutics’s revenue was up 11.7% on a year-over-year basis.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Snyder Capital Management L P increased its position in shares of Halozyme Therapeutics by 18.6% in the fourth quarter. Snyder Capital Management L P now owns 4,064,779 shares of the biopharmaceutical company’s stock worth $163,445,000 after acquiring an additional 637,303 shares in the last quarter. Royce & Associates LP acquired a new position in Halozyme Therapeutics in the 1st quarter valued at approximately $1,276,000. AMI Asset Management Corp increased its stake in Halozyme Therapeutics by 5.1% in the 1st quarter. AMI Asset Management Corp now owns 248,461 shares of the biopharmaceutical company’s stock valued at $9,909,000 after buying an additional 12,160 shares during the period. Gotham Asset Management LLC increased its stake in Halozyme Therapeutics by 92.6% in the 4th quarter. Gotham Asset Management LLC now owns 45,133 shares of the biopharmaceutical company’s stock valued at $1,815,000 after buying an additional 21,698 shares during the period. Finally, E Fund Management Co. Ltd. increased its stake in Halozyme Therapeutics by 53.7% in the 1st quarter. E Fund Management Co. Ltd. now owns 7,726 shares of the biopharmaceutical company’s stock valued at $308,000 after buying an additional 2,699 shares during the period. 91.72% of the stock is owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

(Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Featured Articles

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.